Clinical Trials Browser

Phase 2 × tocilizumab × Lymphoid × Clear all

Lymphoma, Non-Hodgkin

NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Phase 2 Recruiting

70 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03434730 2025-04-22

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Phase 2 Completed

46 enrolled

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT05833763 2024-01-08

GOlDiLOX

Phase 2 Recruiting

42 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Phase 2 Completed

8 enrolled 18 charts

LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Clinical Trials

MorningSun

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

GOlDiLOX

Tocilizumab for KSHV-Associated Multicentric Castleman Disease